Houston-based neurotechnology company, based on Rice University research, developing a minimally invasive, wirelessly powered implantable brain stimulator (the Motif XCS System) that sits above the dura to treat treatment-resistant depression as an alternative to TMS. It conducted first-in-human stimulation in 2023 and received FDA IDE approval to begin its first clinical trial in 2026. It is a medical-device/neurotech company rather than a psychedelic drug developer.